GHIRMAY HAILE: Open Payments
NPI 1336611169 · LAS CRUCES, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$609 in 36 payments from 9 companies in 2025. Trend: 2023 $367 · 2024 $416 · 2025 $609
Food & beverage: $609
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $222 |
| ABBVIE INC. | 11 | $148 |
| Neurocrine BioSciences, Inc. | 3 | $68 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 3 | $47 |
| Janssen Pharmaceuticals, Inc | 2 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Alkermes, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
Products named: VRAYLAR, UZEDY, INGREZZA, AUSTEDO XR, COBENFY, FANAPT, INVEGA SUSTENNA, CAPLYTA.
Industry payments across NM — which companies pay providers there.
